• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Wentworth Kerry

    4/21/26 4:35:16 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVB alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wentworth Kerry

    (Last)(First)(Middle)
    C/O NUVATION BIO INC.
    1500 BROADWAY, SUITE 1401

    (Street)
    NEW YORK NEW YORK 10036

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Nuvation Bio Inc. [ NUVB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    CHIEF REGULATORY OFFICER
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    04/17/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Class A Common Stock04/17/2026M36,750A$2.9389,750D
    Class A Common Stock04/17/2026S(1)36,750D$5.0144(2)53,000D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Stock Option (Right to Buy)$2.9304/17/2026M36,750 (3)08/28/2032Class A Common Stock36,750$0215,250D
    Explanation of Responses:
    1. Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
    2. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $5.00 to $5.05. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
    3. Option vests as to 25% on the one year anniversary of August 29, 2022, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
    /s/ Stephen Dang, Attorney-in-Fact04/21/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $NUVB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVB

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    11/19/2025$12.00Buy
    B. Riley Securities
    9/30/2025$10.00Buy
    Jefferies
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $NUVB
    SEC Filings

    View All

    SEC Form DEFA14A filed by Nuvation Bio Inc.

    DEFA14A - Nuvation Bio Inc. (0001811063) (Filer)

    4/21/26 10:53:38 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Nuvation Bio Inc.

    144 - Nuvation Bio Inc. (0001811063) (Subject)

    4/17/26 4:39:05 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Nuvation Bio Inc.

    DEF 14A - Nuvation Bio Inc. (0001811063) (Filer)

    4/10/26 11:23:54 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /U P D A T E -- Nuvation Bio Inc./

    In the news release, Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026, issued April 21, 2026 by Nuvation Bio Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026  Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in

    4/21/26 6:00:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

     Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patientsIBTROZI also demonstrated a high overall response rate in TKI-naïve patients at 89.8%Long-term pooled data highlighted in oral and poster presentations at AACR, and TRUST-I data simultaneously published in the Journal of Clinical Oncology, reinforce IBTROZI's manageable safety profile, with low rates of neurologic side effects and no new safety signalsIBTROZI demonstrated robust CNS activity, with an intracranial response rate of 76.5% in TKI-naïve patients and 65.6% in TKI-pretreated patients with brain

    4/21/26 6:00:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

    NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (

    4/20/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:15 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:21 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:19 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wentworth Kerry

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    4/21/26 4:35:16 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Liu Dongfang

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    4/21/26 4:34:07 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Wentworth Kerry

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    4/8/26 4:23:17 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Nuvation Bio

    Truist initiated coverage of Nuvation Bio with a rating of Buy

    11/24/25 8:30:57 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Nuvation Bio with a new price target

    B. Riley Securities initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $12.00

    11/19/25 8:57:29 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Nuvation Bio with a new price target

    Jefferies initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $10.00

    9/30/25 8:57:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

    Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

    10/7/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

    Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

    5/14/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

    Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

    3/28/24 8:00:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Financials

    Live finance-specific insights

    View All

    Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

    NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-461-5787 (

    4/20/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Successfully started 216 patients on IBTROZI® (taletrectinib) in the fourth quarter of 2025, for a total of 432 new patient starts since launch in the second half of June 2025Entered into exclusive licensing and collaboration agreement with Eisai on January 11, 2026, for taletrectinib in Europe and additional countries outside U.S., China and JapanPublished positive Phase 2 study results for safusidenib demonstrating durable responses for the treatment of grade 2 IDH1-mutant gliomaStrong balance sheet with cash, cash equivalents, and marketable securities of $529.2 million as of December 31, 2025Company to host a conference call today at 4:30 pm ETNEW YORK, March 2, 2026 /PRNewswire/ -- Nuva

    3/2/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

    NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, March 2, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the fourth quarter and full year of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +

    2/17/26 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

    SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

    11/12/24 10:32:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

    SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

    10/18/24 4:15:55 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Nuvation Bio Inc.

    SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

    9/10/24 4:51:38 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care